These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 34686187)

  • 1. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
    Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
    PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
    Wang F; Zhang G; Xu T; Ma J; Wang J; Liu S; Tang Y; Jin S; Li J; Xing N
    J Exp Clin Cancer Res; 2024 Jan; 43(1):24. PubMed ID: 38245792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
    Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
    Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
    Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
    Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells.
    Nham T; Poznanski SM; Fan IY; Vahedi F; Shenouda MM; Lee AJ; Chew MV; Hogg RT; Lee DA; Ashkar AA
    J Immunother; 2018; 41(2):64-72. PubMed ID: 29189387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
    Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
    J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.
    Lehmann D; Spanholtz J; Osl M; Tordoir M; Lipnik K; Bilban M; Schlechta B; Dolstra H; Hofer E
    Stem Cells Dev; 2012 Nov; 21(16):2926-38. PubMed ID: 22571679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions
    Oyer JL; Croom-Perez TJ; Dieffenthaller TA; Robles-Carillo LD; Gitto SB; Altomare DA; Copik AJ
    Front Immunol; 2022; 13():861681. PubMed ID: 35464440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma.
    Rujkijyanont P; Chan WK; Eldridge PW; Lockey T; Holladay M; Rooney B; Davidoff AM; Leung W; Vong Q
    Cancer Res; 2013 Apr; 73(8):2608-18. PubMed ID: 23440424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
    Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
    Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
    Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
    PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
    Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
    Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
    Peragine N; Torelli GF; Mariglia P; Pauselli S; Vitale A; Guarini A; Foà R
    Cancer Immunol Immunother; 2015 Feb; 64(2):201-11. PubMed ID: 25341808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.